Business Wire

OAG Acquires Infare and Receives New Investment from Vitruvian Partners

28.7.2023 15:37:00 EEST | Business Wire | Press release

Share

OAG, the world’s leading data platform for the global travel industry, has acquired Infare, the leading provider of competitor air travel data, from Ventiga Capital in a deal valuing the combined entity at over US$500m. Together, OAG and Infare have an exciting journey ahead to leverage a truly market-leading end-to-end data platform to serve mission-critical air travel intelligence needs across the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230728627752/en/

With renowned industry heritage, both businesses share a deep passion for quality, accuracy, and customer-centricity. Together, there is a significant opportunity for OAG and Infare to better serve airline partners and the wider travel ecosystem with high-quality data and innovative solutions.

Infare is the partner of choice for airlines demanding the highest quality competitor air travel data source to support their growth. Combining OAG’s existing data solutions with airfare data creates a compelling proposition for customers who can get a broader picture of supply and demand. This enables customers to forecast resource, evaluate travel demand and competition, and build more complex and innovative models to drive revenue and profitable growth.

Through the acquisition, OAG now grows to over 300 employees globally across 10 offices.

Phil Callow, CEO of OAG, commented:

“The increasing dynamism in global travel and technology is fuelling a need for more sophisticated, granular data to understand, manage and unlock growth in air travel. The acquisition of Infare strengthens our ability to deliver consistent and accurate information across the wider supply and demand value chain. Together, we are enabling new and existing customers to thrive and innovate ahead of their counterparts. I am excited to welcome Infare colleagues to the OAG family.”

Nils Gelbjerg-Hansen, CEO of Infare, commented:

“Access to comprehensive and accurate data is paramount for making informed business decisions. Airlines rely on data to gain valuable insights into customer behaviour, market trends, and operational efficiency. Our technology platform, data sets, and intelligence software complement OAG’s and will greatly benefit our customers worldwide. We see this as a unique opportunity to expand our services and introduce new innovative products for our customers, we are excited about the journey ahead together.”

Both management teams will continue in the Group and will retain a shareholding, with fresh backing provided by Vitruvian Partners.

Ben Johnson, a Partner at Vitruvian, commented:

“OAG and Infare are both clear leaders in their respective global markets. The combination creates additional growth opportunities for both teams. Vitruvian is delighted to support this ambitious technology company and renew our relationship with them for the years to come.”

Niclas Gabrán, Managing Partner at Ventiga Capital Partners, commented:

“It has been a pleasure working together with Nils and his team to build Infare into a leading travel data provider through organic growth and acquisitions. Infare’s next chapter as a part of the OAG family will undoubtedly create further growth opportunities both within and outside the air travel sector.”

About OAG

OAG is the leading data platform for the global travel industry, powering the growth and innovation of the air travel ecosystem since 1929. It has the world’s largest network of flight information, covering the whole journey from planning to customer experience. Customers include airlines, airports, travel technology players, aviation service providers, government agencies, financial institutions, and consultancies. Headquartered in the UK, OAG has operations in the USA, Singapore, Japan, China, and Lithuania. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.

About Infare

Infare is the leading competitor air travel data provider, empowering airlines to make effective pricing decisions. Infare’s mission is to fuel airline systems with high-quality competitor air travel data delivered daily, multiple times a day or live. Founded in 2000 and headquartered in Copenhagen, Denmark, the company has a global reach and presence worldwide. For more information, visit www.infare.com and follow us on LinkedIn.

About Vitruvian Partners

Vitruvian is an independent growth capital firm headquartered in London with a global presence. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning technology, financial services, healthcare, and business and consumer services. Vitruvian is among the largest pools of capital in Europe supporting innovative and higher growth companies. Vitruvian Funds have backed over 90 companies and have assets under management of €15+ billion. Notable investments to date include global market leaders and innovators in their field such as Skyscanner, Sykes Holiday Cottages, CFC Underwriting, CallCredit, Travel Counsellors, Trustpilot, Farfetch, Just Eat, Wise, and Global-e.

About Ventiga Capital Partners

Ventiga is an entrepreneurial and growth-focused investor partnering with exceptional entrepreneurs and management teams to achieve sustainable, profitable growth and transformational value through active, engaged, and responsible ownership. Ventiga invests in profitable growth companies with superior business expansion potential, primarily in the B2B services space.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
pressoffice@oag.com

UK/EMEA /ASPAC
Dom Conolly/ Harvard PR

North America
Chrissy Azevedo
Corporate Ink for OAG

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye